Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Erythropoiesis

Erythropoiesis

Red blood cells (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia, and...

Factors Affecting Erythropoiesis

Factors Affecting Erythropoiesis

The cardiovascular system regulates the number of erythrocytes in the bloodstream to ensure optimal oxygen transport. It also prevents over-proliferation of these cells, which helps to maintain blood viscosity and flow rate.
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Clinical Image-Based Dosimetry of Actinium-225 in Targeted Alpha Therapy.

Cancers·2026

Same author

Therapeutic Applications of Fibroblast Activation Protein (FAP)-Binding Radiopharmaceuticals: Review of Opportunities and Challenges.

Cancers·2025

Same author

cGMP-compliant high-yield automated production of [<sup>18</sup>F]AlF-FAPI-74: optimization of quality control and evaluation of molar dose impact.

EJNMMI radiopharmacy and chemistry·2025

Same author

A Comprehensive Review of SSTR-Based Spect and Pet Imaging in Chronic Inflammatory and Immune-Mediated Diseases.

Journal of clinical medicine·2025

Same author

Low-count whole-body PET denoising with deep learning in a multicenter, multi-tracer and externally validated study.

European journal of nuclear medicine and molecular imaging·2025

Same author

Model-based cost-effectiveness studies in nuclear medicine: an unavoidable fact of life.

European journal of nuclear medicine and molecular imaging·2025

Search research articles

Related Experiment Video

Updated: Jun 11, 2026

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

Eryhtropoetin induced ¹⁸F-PSMA-11 bone marrow sink effect.

Justine Maes¹, Alex Maes^1,2, Kristoff Muylle³

¹Department of Nuclear Medicine, AZ Groeninge, Kortrijk, Belgium.

European Journal of Nuclear Medicine and Molecular Imaging

|June 9, 2026

Summary

A patient receiving Aranesp before prostate cancer imaging showed unexpected diffuse bone marrow uptake on 18F-PSMA-11 PET/CT. This may be due to Aranesp-induced neovascularization, potentially affecting treatment interpretation.

Keywords:

18F-PSMA-11 PET/CT imaging Bone marrow sink effect Erythropoietin

Related Experiment Videos

Last Updated: Jun 11, 2026

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

Area of Science:

Nuclear Medicine
Oncology
Radiopharmacology

Background:

Metastatic prostate cancer requires accurate restaging after treatment.
PSMA-targeting PET/CT is crucial for visualizing prostate cancer spread.
¹⁷⁷Lu-PSMA-617 therapy is a treatment option for advanced prostate cancer.

Purpose of the Study:

To investigate an unusual diffuse bone marrow uptake observed on ¹⁸F-PSMA-11 PET/CT in a patient post-¹⁷⁷Lu-PSMA-617 treatment.
To determine the potential cause of this atypical imaging finding.
To highlight implications for interpreting PSMA-PET/CT scans in patients receiving specific therapies.

Main Methods:

¹⁸F-PSMA-11 PET/CT restaging was performed on a patient with metastatic prostate cancer.
Imaging findings were compared with CT scans and previous PSMA-PET/CT scans.
Patient history, including recent medication, was reviewed.

Main Results:

Intense, homogeneous ¹⁸F-PSMA-11 uptake was observed throughout the bone marrow.
CT confirmed bone metastases, but not diffuse marrow involvement.
Previously known metastases showed reduced or absent uptake compared to pre-treatment scans.
This finding was unique to the patient and not seen in others using the same tracer batch.
The patient had received recombinant human erythropoietin (Aranesp) 24 hours prior to imaging.

Conclusions:

Recombinant human erythropoietin (Aranesp) administration may induce systemic neovascularization, leading to diffuse bone marrow uptake on ¹⁸F-PSMA-11 PET/CT.
This effect can outcompete tumor lesions for radiotracer, potentially causing decreased visibility of metastases.
Clinicians should consider recent Aranesp use to avoid misinterpreting diffuse bone marrow uptake and potential undertreatment.
The neovascularization effect of erythropoietin can last 7-10 days, impacting scan interpretation during this period.